Indian Clinical Trials Market Size To Reach $3.87 Billion By 2030

Indian Clinical Trials Market Growth & Trends

The Indian clinical trials market size is expected to reach USD 3.87 billion by 2030, registering a CAGR of 8.3% from 2023 to 2030, according to a new report by Grand View Research, Inc. The globalization of clinical trials, growing disease variation and prevalence in the country, adoption of new technology in clinical research, and increasing R&D promoting outsourcing are the key factors driving the market.

India is populated with 1.3 billion individuals with varying genetic backgrounds and a large treatment-naïve patient pool for the development of therapeutics on a range of disease conditions. Furthermore, the economic, environmental, and ecological variations in the 28 states and 8 union territories present the most diverse disease profile. Apart from this, the cost of carrying out clinical trials in India is nearly 40-70% less when compared to that in Europe or the U.S. Thus, the cost efficiency, along with skill sets and ease of doing business, is anticipated to fuel the market growth.

The increasing R&D investments by pharmaceutical and biopharmaceutical companies have led to increased demand for contract research organizations and outsourcing of trials in order to curb the cost. Furthermore, outsourcing enables the drug companies to focus on their core competencies and aids in improving their productivity, thus facilitating the outsourcing of trials in India. The COVID-19 pandemic has improved the market in the country. Several companies globally are conducting clinical trials for COVID-19 vaccines in India. Moreover, government initiatives promoting clinical trials for COVID-19 therapeutics in the country have promoted market growth.

 Request a free sample copy or view report summary: Indian Clinical Trials Market Report

Indian Clinical Trials Market Report Highlights

• By phase, the phase I segment is projected to register the fastest growth rate of 10.0% over the forecast period. This can be attributed to the increasing R&D spending by pharmaceutical and biopharmaceutical companies

• The interventional trials study design segment held the largest revenue share of over 40.8% in 2022 owing to the greater accuracy offered by them as compared to observational study design

• The oncology indication segment held the largest revenue share of over 24.9% in 2022 due to the increasing prevalence of the disease condition and the consequent rise in demand for innovative therapies for cancer

Indian Clinical Trials Market Segmentation

Grand View Research has segmented the Indian clinical trials market based on phase, study design, and indication:

Indian Clinical Trials Phase Outlook (Revenue in USD Million, 2018 - 2030)

• Phase I

• Phase II

• Phase III

• Phase IV

Indian Clinical Trials Study Design Outlook (Revenue in USD Million, 2018 - 2030)

• Interventional Trials

• Observational Trials

• Expanded Access Trials

Indian Clinical Trials Indication Outlook (Revenue in USD Million, 2018 - 2030)

• Autoimmune/Inflammation

  • Rheumatoid Arthritis

  • Multiple Sclerosis

  • Osteoarthritis

  • Irritable Bowel Syndrome (IBS)

  • Others

• Pain Management

  • Chronic Pain

  • Acute Pain

• Oncology

  • Blood Cancer

  • Solid Tumors

  • Other

• CNS Condition

  • Epilepsy

  • Parkinson's Disease (PD)

  • Huntington's Disease

  • Stroke

  • Traumatic Brain Injury (TBI)

  • Amyotrophic Lateral Sclerosis (ALS)

  • Muscle Regeneration

  • Others

• Diabetes

• Obesity

• Cardiovascular

• Others

List Of Key Players Indian Clinical Trials Market

• IQVIA HOLDINGS INC.

• PAREXEL International Corporation

• Pharmaceutical Product Development (PPD) LLC

• Charles River Laboratory

• ICON PLC

• PRA Health Inc.

• Chiltern International LTD.

• Syneos Health Inc.

• SGS SA

• Syngene International Limited

• Aurigene Discovery Technologies Limited

• Aragen Life Sciences

• Abiogenesis Clinpharm Pvt Ltd

• Accelsiors

• Accutest Global.

• Clario

• Cliantha Research

• Cliniminds

• CliniRx

• JSS Medical Research